Compare ATYR & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | AOMR |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 224.3M |
| IPO Year | 2015 | 2021 |
| Metric | ATYR | AOMR |
|---|---|---|
| Price | $0.74 | $8.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $8.75 | ★ $11.13 |
| AVG Volume (30 Days) | ★ 2.2M | 96.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 14.70% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.73 |
| Revenue | $190,000.00 | ★ $34,705,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | $16.56 |
| P/E Ratio | ★ N/A | $11.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $7.36 |
| 52 Week High | $7.29 | $10.88 |
| Indicator | ATYR | AOMR |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 48.30 |
| Support Level | $0.70 | $8.68 |
| Resistance Level | $0.83 | $8.96 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 26.75 | 33.61 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.